Sklar S H, Blue W T, Alexander E J, Bodian C A
JAMA. 1985 Mar 8;253(10):1427-30. doi: 10.1001/jama.253.10.1427.
Thirty-two adults were enrolled in a randomized, placebo-controlled double-blind trial of intramuscular injections of gel-sustained adenosine monophosphate (AMP) given three times a week for up to four weeks for acute herpes zoster. Adenosine monophosphate moderately reduced the pain soon after the start of treatment, decreased desquamation time, and promoted faster healing of the skin than placebo treatment. Adenosine monophosphate treatment reduced virus shedding and cleared the virus faster than in placebo-treated subjects. At the end of the initial four-week treatment period, 88% of AMP-treated patients were pain free, as opposed to only 43% in the placebo group. After four weeks, all patients who had not recovered from pain started receiving AMP treatment without breaking the code. All these patients recovered from pain within three weeks after initiation of treatment. No recurrence of pain or lesions was experienced from three to 18 months after the end of treatment. Adenosine monophosphate, a natural cellular metabolite, showed no side effects or toxicity during and after the treatment.
32名成年人参与了一项随机、安慰剂对照双盲试验，该试验针对急性带状疱疹患者，每周进行三次肌肉注射凝胶缓释型单磷酸腺苷（AMP），持续四周。与安慰剂治疗相比，单磷酸腺苷在治疗开始后不久能适度减轻疼痛，缩短脱屑时间，并促进皮肤更快愈合。单磷酸腺苷治疗比安慰剂治疗能减少病毒排出并更快清除病毒。在最初四周的治疗期结束时，接受AMP治疗的患者中有88%无痛，而安慰剂组仅为43%。四周后，所有未从疼痛中恢复的患者开始接受AMP治疗，且不打破盲法。所有这些患者在开始治疗后的三周内均从疼痛中康复。治疗结束后三至18个月内未出现疼痛复发或皮损。单磷酸腺苷作为一种天然细胞代谢产物，在治疗期间及之后均未显示出副作用或毒性。
